Interchange Capital Partners LLC Reduces Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Interchange Capital Partners LLC trimmed its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 28.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,451 shares of the company’s stock after selling 5,833 shares during the quarter. Interchange Capital Partners LLC’s holdings in Intellia Therapeutics were worth $163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $43,177,000. Contrarius Group Holdings Ltd purchased a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $11,798,000. State Street Corp raised its position in Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the period. Vanguard Group Inc. boosted its stake in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock worth $118,816,000 after acquiring an additional 562,249 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $4,793,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. HC Wainwright assumed coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 target price on the stock. Wedbush reiterated a “neutral” rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. BMO Capital Markets reduced their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Citigroup raised their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Insider Activity

In related news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by company insiders.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $9.31 on Tuesday. The company has a market cap of $963.74 million, a PE ratio of -1.71 and a beta of 1.97. The firm’s 50 day moving average price is $10.07 and its 200-day moving average price is $14.05. Intellia Therapeutics, Inc. has a 52-week low of $8.30 and a 52-week high of $28.23.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.